Great Debate: SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction

被引：2
|
作者：
Packer, Milton [1 ,2 ]
Cleland, John G. F. [3 ]
Bauersachs, Johann [4 ]
机构：
[1] Baylor Heart & Vasc Inst, Dallas, TX USA
[2] Imperial Coll, London, England
[3] Univ Glasgow, British Heart Fdn Ctr Res Excellence, Sch Cardiovasc & Metab Hlth, Glasgow, Scotland
[4] Hannover Med Sch, Dept Cardiol & Angiol, Carl Neuberg Str 1, D-30625 Hannover, Germany
来源：
EUROPEAN HEART JOURNAL | 2024年 / 45卷 / 25期
关键词：
Heart failure; SGLT2; inhibitor; Pharmacotherapy; Foundational drugs; Hospitalization; EMPAGLIFLOZIN; RISK; DAPAGLIFLOZIN; HYPERTENSION; METAANALYSIS; DIURETICS; MORTALITY; MEDICINE; BENEFITS; OUTCOMES;
D O I：
10.1093/eurheartj/ehae300
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Graphical Abstract SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction. ARNI, angiotensin receptor-neprilysin inhibitor; CV, cardiovascular; GRMT, guideline-recommended medical therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; MRA, mineralocorticoid receptor antagonist; SGLT2i, sodium-glucose cotransporter 2 inhibitor.
引用
收藏
页码：2186 / 2196
页数：11
相关论文
共 50 条
  • [41] Left ventricular reverse remodelling and prognosis of patients treated with SGLT2 inhibitors for heart failure with reduced ejection fraction.
    Tinoco, M. Mariana
    Cardoso, F.
    Dias, G.
    Pereira, T.
    Faria, B.
    Almeida, F.
    Leite, S.
    Lourenco, A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 58 - 58
  • [42] SGLT2 inhibitors in heart failure with reduced ejection fraction without diabetes mellitus: why are patients outside the magic circle?
    Basile, P.
    Monitillo, F.
    Santoro, D.
    Soldato, N.
    Siena, P.
    Sturda, F.
    Carella, M. C.
    Ciccone, M. M.
    Guaricci, A. I.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 76 - 76
  • [43] Improvement in Left and Right Ventricular Function after Introduction of SGLT2 Inhibitors in Heart Failure Outpatients with Reduced Ejection Fraction
    Alcidi, Gianmarco
    Pugliese, Rosanna
    Ioannoni, Sara
    Romano, Matteo
    Palmieri, Gianpaolo
    Tabella, Erika
    Correale, Michele
    Di Biase, Matteo
    Brunetti, Natale Daniele
    Iacoviello, Massimo
    CLINICS AND PRACTICE, 2023, 13 (06) : 1303 - 1312
  • [44] SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction A Paradigm Shift Toward Dual Cardio-Renal Protection
    Rastogi, Tripti
    Girerd, Nicolas
    HEART FAILURE CLINICS, 2022, 18 (04) : 561 - 577
  • [45] Monitoring SGLT2 inhibition effectiveness on pulmonary systolic pressure in heart failure with reduced ejection fraction
    Stracqualursi, Marco
    Nemola, Giulia
    Santangelo, Gloria
    Moscardelli, Silvia
    Bursi, Francesca
    Guazzi, Marco
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2025, 428
  • [46] The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction
    Genuardi, Michael, V
    Mather, Paul J.
    THERAPEUTIC ADVANCES IN CARDIOVASCULAR DISEASE, 2021, 15
  • [47] SGLT2 INHIBITION IN HEART FAILURE WITH A REDUCED EJECTION FRACTION: HOW MANY PATIENTS WOULD BENEFIT?
    Hooper, Jacquelyn
    Shaw, Steven
    Callan, Paul
    Williams, Simon
    HEART, 2021, 107 : A115 - A115
  • [48] SGLT2 inhibitors DELIVER benefits in heart failure independently of ejection fraction and diabetes: end of the line or need for new studies?
    Volpe, Massimo
    Pedicino, Daniela
    EUROPEAN HEART JOURNAL, 2022, 43 (44) : 4614 - 4615
  • [49] SHOULD CATHETER ABLATION BE THE FIRST LINE TREATMENT IN ATRIAL FIBRILLATION PATIENTS OF HEART FAILURE WITH REDUCED EJECTION FRACTION?
    Malik, Aaqib H.
    Malik, Senada
    Aronow, Wilbert
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 331 - 331
  • [50] SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: Finding the right patients to treat
    Girerd, Nicolas
    Zannad, Faiez
    JOURNAL OF INTERNAL MEDICINE, 2023, 293 (05) : 550 - 558
12345